Compare GLP & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | MPLT |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | 4700 | 133 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | GLP | MPLT |
|---|---|---|
| Price | $49.26 | $27.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $46.00 | $32.67 |
| AVG Volume (30 Days) | 79.2K | ★ 249.6K |
| Earning Date | 05-08-2026 | 05-28-2026 |
| Dividend Yield | ★ 6.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $64.13 | N/A |
| Revenue Next Year | $11.74 | N/A |
| P/E Ratio | $23.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.58 | $12.24 |
| 52 Week High | $56.51 | $33.28 |
| Indicator | GLP | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 46.56 |
| Support Level | $45.18 | $26.20 |
| Resistance Level | N/A | $31.88 |
| Average True Range (ATR) | 1.67 | 2.22 |
| MACD | -0.08 | -0.24 |
| Stochastic Oscillator | 50.27 | 38.99 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.